Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA phase IIb study of AZD5004 in adults with obesity or overweight with comorbidity
jRCT2051240162Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing AZD5004 with Placebo (2 arms). Primary endpoints: Percent change in body weight from baseline at Week 26 and Proportion of participants with weight loss of 5% or more from baseline at Week 26. Started Nov 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051240162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240162.